New biomarkers in T-cell lymphomas.
Bettina Bisig, Philippe Gaulard, Laurence De Leval

To cite this version:

HAL Id: inserm-00693167
http://www.hal.inserm.fr/inserm-00693167
Submitted on 2 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
New biomarkers in T-cell lymphomas

Bettina Bisig\textsuperscript{1,2} MD, Philippe Gaulard\textsuperscript{3,4,5} MD, Laurence de Leval\textsuperscript{1,2,6,*} MD PhD

\textsuperscript{1}Department of Pathology, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium;
\textsuperscript{2}Laboratory of Experimental Pathology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA) – Research, University of Liège, Belgium;
\textsuperscript{3}Department of Pathology, Assistance Publique – Hôpitaux de Paris (AP–HP), Groupe hospitalier Henri Mondor – Albert Chenevier, Créteil, France;
\textsuperscript{4}Institut National de la Santé et de la Recherche Médicale (INSERM), Unité U955, Créteil, France;
\textsuperscript{5}Université Paris-Est, Faculté de Médecine, Créteil, France;
\textsuperscript{6}Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

* Corresponding author

Addresses:

Bettina Bisig, Department of Pathology, CHU Sart Tilman, B-4000 Liège, Belgium. Tel. ++32 4 366 24 10. Fax : ++32 4 366 29 19. E-mail : bettina.bisig@ulg.ac.be

Philippe Gaulard, Department of Pathology, Hôpital Henri Mondor, F-94010 Créteil, France. Tel.: +33 1 49 81 27 43. Fax : +33 1 49 81 27 33. E-mail: philippe.gaulard@hmn.aphp.fr

Laurence de Leval, Institute of Pathology, CHUV, CH-1011 Lausanne, Switzerland. Tel.: ++41 21 314 71 94. Fax: ++41 21 314 72 05. E-mail: laurence.deleval@chuv.ch
Abstract

Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies characterized by an aggressive clinical course and a mostly poor outcome with current treatment strategies. The recent genome-wide molecular characterization of several entities has provided novel insights into their pathobiology and led to the identification of new biomarkers with diagnostic, prognostic or therapeutic implications for PTCL patients. Cell lineage and differentiation antigens (markers of γδ or NK lineage, of cytotoxicity, of follicular helper T cells) reflect the tumour’s biological behaviour, and their detection in tissue samples may refine the diagnostic and prognostic stratification of the patients. Previously unrecognized gene rearrangements are being discovered (ITK-SYK translocation, IRF4/MUM1 and DUSP22 rearrangements), and may serve as diagnostic genetic markers. Deregulated molecules within oncogenic pathways (NF-κB, Syk, PDGFRα) and immunoreactive cell-surface antigens (CD30, CD52) have been brought to the fore as potential targets for guiding the development of novel therapies.

Key words

peripheral T-cell lymphomas; biomarkers; translocations; gene expression profiling; targeted therapy; prognosis
Introduction

Malignancies derived from mature T cells and natural killer (NK) cells, collectively referred to as peripheral T-cell lymphomas (PTCLs), constitute a heterogeneous group of uncommon neoplasias, accounting altogether for less than 15% of all non-Hodgkin lymphomas worldwide [1]. Although the aetiology of most PTCL subtypes is poorly understood, infections by the Epstein-Barr virus (EBV) or the human T-lymphotropic virus type 1 (HTLV-1) contribute to the development of a few entities more prevalent in Asia and Latin America where these viruses are endemic [1, 2].

The pathological diagnosis of PTCLs is often challenging, owing to a broad morphologic and immunophenotypic variability within and significant overlaps across distinct entities; and to the lack – with few exceptions – of specific, entity-defining, genetic alterations. Conversely, the clinical features are critical to the classification of PTCLs, which are listed according to their predominant site of involvement as disseminated/leukaemic, extranodal, cutaneous or nodal entities (Table 1) [2].

With few exceptions, PTCLs almost uniformly exhibit resistance to standard chemotherapy regimens and have a poor clinical outcome [3, 4]. The 5-year overall survival (OS) rate is as low as 30% for peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and angioimmunoblastic T-cell lymphoma (AITL), contrasting with 70% for anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL). Most extranodal and leukaemic subtypes have an even more aggressive clinical course, with a 5-year OS ranging between 7% and 32% [3]. More effective treatment modalities are clearly needed.
Over the past years, novel insights have been gained into the pathobiology of PTCLs (reviewed in [5, 6]). Importantly, genome-wide molecular characterization of several PTCL entities has consented to refine their diagnostic criteria and reveal novel diagnostic biomarkers [7-11]. The delineation of molecular subgroups has been shown to be of interest for the prognostic stratification of patients within some PTCL categories [10, 12-14]. By comparison with the molecular signatures of benign T-cell populations, gene expression analyses have also contributed to the identification of oncogenic pathways, guiding the development of novel targeted therapies [11, 15-18]. Moreover, previously unrecognized recurrent genetic alterations have been recently described [19-21]. Concurrently, a number of immunotherapeutic agents are being developed or under investigation, targeting cell-surface molecules that are variably expressed across PTCL entities (reviewed in [22, 23]).

This review will focus on the most relevant of these new molecular biomarkers, by virtue of their diagnostic, prognostic or therapeutic implications (summarized in Table 2).
**Lineage / differentiation markers**

While ascribing lymphoid neoplasms to a normal cell counterpart is a major principle for their classification according to the World Health Organization (WHO) [2], yet many PTCL entities do not conform to this criterion as their cellular origin remains poorly characterized (Fig. 1). This is likely due to the complexity of normal T-cell differentiation, characterized by marked functional diversity but also evidence of functional overlap and plasticity between T- and NK-cell subsets. These features might in turn account for frequent aberrations and a pronounced variability in the phenotype within distinct PTCL categories (reviewed in [24-26]). Over the past years it has become clear that cell lineage or differentiation traits represent major determinants of the biology of these neoplasms, relevant to their classification and prognosis, and significant progresses have been achieved in the identification of the cellular derivation of several PTCL entities.

**γδ T-cell lineage**

Among normal mature T cells, a major distinction is based on the structure of the T-cell receptor (TCR), composed of either the αβ chains or the γδ chains. While αβ T cells (including CD4+ (mainly helper) and CD8+ (mainly cytotoxic) subpopulations) belong to the adaptive immune system featuring specificity and memory, γδ T cells participate in the innate immune responses as a first-line defence (together with NK cells) and are mostly CD4-/CD8- cells located within the skin, the mucosae and the spleen [27].

Reflecting the paucity and distribution of normal γδ T cells, PTCLs derived from T cells of the γδ lineage (γδ PTCLs) comprise a few rare, highly aggressive, extranodal
malignancies, with peculiar clinicopathologic features reflecting their cell of origin [2, 27, 28]. Hepatosplenic T-cell lymphoma (HSTL) is the prototype and the first entity initially defined by its γδ derivation (although subsequently rare cases with an αβ phenotype and a similar clinicopathologic presentation were reported [29]). HSTL occurs predominantly in young male adults and may arise in the setting of chronic immune suppression or prolonged antigenic stimulation, particularly following long-term immunosuppressive therapy for solid organ transplantation or in children treated by azathioprine and infliximab for Crohn’s disease. The disease typically presents with hepatosplenomegaly, thrombocytopenia and systemic symptoms. Histopathology reveals a predominantly intrasinusoidal involvement of the spleen, liver and bone marrow by monotonous medium-sized T cells with a non-activated cytotoxic phenotype (see below) [30]. Genetically most cases harbour an isochromosome 7q [31]. The clinical course of the disease is rapidly progressive with an extremely dismal 5-year OS of only 7% [3].

Among cutaneous T-cell lymphomas, it has been recognized that entities with a γδ phenotype share an aggressive behaviour and are associated with a significantly shorter survival when compared with their αβ counterparts [32, 33], and hence primary cutaneous γδ PTCLs, irrespective of the histological pattern, are grouped under a single entity [2]. Similar cases presenting in mucosal sites may possibly be related [2, 33, 34]. In contrast with HSTL, these non-hepatosplenic muco-cutaneous γδ PTCLs carry an activated cytotoxic phenotype (see below), and are clinically and morphologically more heterogeneous [28, 31]. Accordingly, recent GEP studies have evidenced that, while HSTLs feature a distinct and homogeneous molecular signature, non-hepatosplenic γδ PTCLs do not spontaneously cluster together in unsupervised expression analyses [35, 36]. This clinicopathologic and molecular heterogeneity favours the existence of several
biologically distinct disease entities within the spectrum of non-hepatosplenic \( \gamma \delta \) PTCLs, encouraging the study of larger series of samples from different anatomic sites, to gain new insights into their pathobiological relationship and refine their classification [28, 31, 35-37].

Until recently, expression of the \( \gamma \delta \) TCR in lymphoma samples could only be assessed by flow cytometry or by immunohistochemistry on frozen sections. As a consequence, in routinely processed fixed material the \( \gamma \delta \) phenotype was extrapolated from the negativity for the \( \alpha \beta \) TCR (recognized by the anti-\( \beta F1 \) antibody) [31]. Monoclonal antibodies detecting the constant region of the TCR\( \gamma \) chain (C\( \gamma M1 \)) or TCR\( \delta \) chain (TCR\( \delta 1 \)) in paraffin sections have now been made available [37, 38], and will valuably assist in the identification of these rare – and probably hitherto underdiagnosed – malignancies [28].

**NK-cell receptors (NKRs)**

Although immunohistochemistry can be employed to determine the \( \alpha \beta \) versus \( \gamma \delta \) lineage of a T-cell population, it is not sufficient to assess its clonality. Instead, demonstration of T-cell monoclonality requires genetic testing, most commonly PCR assays establishing the rearrangement patterns of the TCR genes in the sample of interest. Conversely, TCR testing does not provide any information in NK-cell proliferations, since NK cells do not rearrange their TCR genes. In that setting, clonality analysis can be performed indirectly by immunophenotyping of cell-surface markers such as NK-cell receptors (NKRs). The latter include killer cell immunoglobulin-like receptors (KIRs), which recognize major histocompatibility complex (MHC) class I molecules and provide signals that regulate NK-cell functions. Since KIRs comprise multiple isoforms, a restricted KIR repertoire
can be used as a surrogate marker of clonal cellular expansion. This tool has proven to be particularly useful in the evaluation of NK-cell lymphocytosis by flow cytometry, for the differential diagnosis between reactive conditions and neoplastic diseases such as chronic lymphoproliferative disorders of NK cells (CLPD-NKs) [39, 40]. Restricted KIR expression has also been demonstrated in extranodal NK/T-cell lymphomas (NKTCLs) by immunohistochemistry on frozen sections [41].

In addition to NK-cell lymphoproliferations, T-cell large granular lymphocytic leukaemia (T-LGL) and subsets of T-cell-derived extranodal cytotoxic PTCLs (i.e. HSTL and enteropathy-associated T-cell lymphoma (EATL)) have been shown to share the expression of NKR s [39, 42, 43], reflecting the close functional relationship between NK cells and cytotoxic T cells.

Interestingly, a peculiar KIR – namely CD158k/KIR3DL2 – is aberrantly expressed by Sézary cells, and the determination of circulating CD4+CD158k+ cells by flow cytometry has been proposed as a tool for the evaluation and follow-up of patients with Sézary syndrome [44, 45].

**Cytotoxic markers**

Cytotoxicity is mediated through the release of cytotoxic granules-associated molecules, including perforin and several granzymes, and is a property shared by functional NK cells, γδ T cells and CD8+ cytotoxic T cells (of the αβ lineage), as well as several PTCL entities (summarized in Table 3) [2]. In addition to providing a mechanistic explanation to some manifestations of these neoplasms (e.g. preferential involvement of extranodal sites, mirroring the tropism of normal γδ T cells and NK cells; and common prominent
intratumoral apoptosis), the demonstration of a cytotoxic immunophenotype may be of diagnostic or prognostic significance [2, 10, 46, 47].

Perforin, granzyme B and T-cell intracellular antigen-1 (TIA-1) represent the most useful cytotoxic markers for diagnostic purposes, and can routinely be identified by immunohistochemistry on tissue sections. While TIA-1 is detected in both resting (non-activated) and activated cytotoxic cells, the expression of perforin and granzyme B is a feature of activated cytotoxic cells [48]. Granzyme H, recently validated as a marker of NKTCL, can be detected by immunohistochemistry and may thus represent a novel helpful marker assisting in the differential diagnosis between NKTCLs and other cytotoxic PTCLs [11].

Within the heterogeneous PTCL, NOS category, Iqbal et al. identified a distinct molecular subgroup, characterized by the upregulation of numerous cytotoxicity-related genes and by a significant enrichment in transcripts associated with normal activated CD8+ T cells [10]. Noteworthily, the patients within this group had an inferior survival compared to the other PTCL, NOS cases, in line with previous immunohistochemistry-based reports [46, 47].

**Follicular helper T (T<sub>FH</sub>)-cell markers**

The majority of PTCLs display a CD4+ immunophenotype, with a molecular signature closer to activated than to resting T cells [17]. CD4+ T cells comprise several functionally different subsets, including the recently characterized follicular helper T cells (T<sub>FH</sub> cells), which have gained increasing interest as the critical regulators of antigen-specific B-cell immune responses [49, 50]. T<sub>FH</sub> cells normally reside in the light zone of reactive germinal centres, and differ from other T-cell subsets by the expression
of distinctive transcription factors, cell-surface molecules and cytokines (T\textsubscript{FH}-cell markers, see below) [51, 52].

An essential advance in the histogenetic understanding of PTCLs was the recent identification of the T\textsubscript{FH} cell as the cell of origin of AITL, a distinct entity amid PTCLs [7, 10, 16]. AITL is defined by a constellation of clinical and pathologic features. The patients typically present in their 6\textsuperscript{th} or 7\textsuperscript{th} decade with generalized lymphadenopathy, hepatosplenomegaly, B symptoms, skin rash and/or pruritus, and polyclonal hypergammaglobulinemia. Peculiar histopathologic features include neoplastic clear cells showing an aberrant expression of CD10, a conspicuous polymorphic reactive infiltrate, prominent arborizing vessels, increased follicular dendritic cell meshworks, and expansion of EBV-infected B blasts (reviewed in [25, 53]). In addition, as a corollary of – and initial hint to – their T\textsubscript{FH}-cell derivation, AITL tumour cells characteristically express several T\textsubscript{FH}-cell markers, including the CXCL13 chemokine [54-56], the cell-surface molecules PD-1/CD279 [56, 57], ICOS [58] and CD200 [59], the adaptor molecule SAP [60], and the transcription factors Bcl-6 [61] and c-Maf [62]. In practice, the immunohistochemical demonstration of a T\textsubscript{FH}-like phenotype is a very helpful adjunct to support the diagnosis of AITL, particularly in morphologically challenging cases [53]. Noteworthily, a small subset of nodal lymphomas classified as PTCLs, NOS also appears to express T\textsubscript{FH}-cell markers and may harbour a few AITL-like histologic features, questioning the criteria that define the borders between these entities [7, 63, 64].

Interestingly, screening of PTCLs has evidenced the expression of T\textsubscript{FH}-cell markers in other PTCL subsets [65]. The latter comprise most PTCLs, NOS featuring a follicular growth pattern, i.e. the follicular variant of PTCL, NOS (PTCL-F) of which a subset harbours the t(5;9)/\textit{ITK-SYK} translocation (see below) [64, 66, 67]; and primary
cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma [68], a provisional entity within primary cutaneous PTCLs, often presenting as a solitary skin nodule in the head and neck area with an indolent clinical course [69].
Cell-surface markers

Along the lines of the anti-CD20 monoclonal antibody rituximab, which has revolutionized the treatment and outcome of B-cell lymphoma patients, efforts have been undertaken to develop therapeutic antibodies targeting cell-surface molecules in PTCLs [22]. Among these, CD30 and CD52 have so far revealed as the most promising targets.

CD30

CD30 (TNFRSF8), a transmembrane glycoprotein of the tumour necrosis factor receptor (TNFR) superfamily, is involved in signal transduction via the activation of the NF-κB pathway and the mitogen-activated protein kinases (MAPKs), ultimately modulating cell growth, proliferation and apoptosis [70]. In reactive lymphoid tissues, CD30 is a non-lineage-specific activation marker expressed by scattered B and T immunoblasts. Among PTCLs, strong and homogeneous CD30 expression is a hallmark feature of ALCLs, irrespective of their ALK gene status, and of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. A subset of cases in virtually all PTCL entities may also express CD30 but at variable and generally lower levels [2, 71].

The CD30 antigen has recently emerged as a novel therapeutic target in patients with CD30+ lymphoproliferations including ALCLs. Indeed, although most ALK+ ALCLs can be cured with first-line chemotherapy regimens, approximately 10-30% of patients are refractory or relapse after initial remission. Some of these patients may respond to salvage chemotherapy and autologous stem cell transplantation, but those who progress have a poor prognosis and treatment options at this stage are limited. ALK-
ALCL, on the other hand, is associated with a more aggressive clinical behaviour and a poorer response to both primary and second-line therapeutic strategies [72].

In the recently developed brentuximab vedotin (SGN-35), an anti-CD30 antibody has been linked to monomethyl auristatin E, a tubulin inhibitor inducing cell cycle arrest and apoptosis [73, 74]. Early clinical trials have demonstrated striking activity of this antibody-drug conjugate in the treatment of patients with relapsed or refractory CD30+ lymphomas, yielding complete remission rates of around 60% in ALCL patients, with limited toxicity (reviewed in [74, 75]). The potential benefits of incorporating this promising agent into established chemotherapy regimens deserve to be further investigated, including as front-line therapy and possibly for patients with CD30+ PTCLs other than ALCL, such as CD30+ PTCLs, NOS, bearing a much poorer prognosis with conventional treatment approaches [72].

**CD52**

CD52 is a cell-surface glycoprotein of unknown function expressed by most normal B and T cells, monocytes and macrophages, but not on haemopoietic progenitors. The presence of CD52 antigen on the surface of malignant lymphocytes has been exploited therapeutically as the target of alemtuzumab (Campath-1H), a humanized anti-CD52 monoclonal antibody inducing complement-mediated cell lysis, antibody-dependent cell cytotoxicity and apoptosis [76, 77]. Several clinical trials have demonstrated the activity of alemtuzumab against PTCLs, particularly T-cell prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphomas (CTCLs) (reviewed in [23, 77]). In PTCL, NOS and AITL, promising responses have been observed in association with conventional
polychemotherapy regimens, although frequently with major hematologic toxicity and infectious complications (reviewed in [23, 78]).

An open question remains the delineation of the histological subtypes that could more efficiently be targeted by an anti-CD52 immunotherapy. By immunohistochemistry on paraffin sections, 30-50% of AITLs, PTCLs, NOS and NKTCLs but only a small minority of ALCLs were CD52 positive [76, 79, 80]. Conversely, by immunofluorescence on frozen tissues and/or by flow cytometry the detection rate of CD52 was generally higher, reaching 90-100% for AITLs, PTCLs, NOS and adult T-cell leukaemias/lymphomas (ATLLs), and 6-50% for ALCLs [81, 82]. GEP studies, on the other hand, have demonstrated a lower CD52 expression level in PTCLs, NOS compared to normal T cells [79], and in CD30+ PTCLs, NOS compared to CD30- PTCLs, NOS [7].

Surprisingly, despite this apparent heterogeneity among PTCLs, only very few studies have correlated the expression of CD52 by the neoplastic cells to the response to alemtuzumab, with divergent conclusions [83, 84]. Further studies are warranted to determine the predictive value of CD52 detection in PTCL samples, and the technique most suitable for this detection in routine settings (immunohistochemistry and/or flow cytometry).
**Recurrent chromosomal translocations**

Characteristic chromosomal translocations are a hallmark feature of most B-cell lymphomas, often involving the promoter of an immunoglobulin locus and a cellular oncogene which is thereby upregulated, offering both an explanation for the mechanism underlying their transformation and a useful diagnostic tool. Recurrent structural genetic alterations are also commonly observed in T-cell lymphoblastic neoplasms [5]. Conversely, the only PTCL entity that has been long recognized in association with a specific gene rearrangement is ALK+ ALCL, carrying ALK gene rearrangements [85]. Today this scenario is changing rapidly, as novel recurrent genetic alterations are being discovered in PTCLs, most recently as a result of next generation sequencing technologies combined with powerful bioinformatic algorithms [21], and their list is expected to be growing over the next few years.

**ALK rearrangements**

The anaplastic lymphoma kinase (ALK, also designated as CD246) is a transmembrane receptor tyrosine kinase, member of the insulin receptor superfamily, whose normal expression is restricted to scattered cells in the central nervous system. Aberrant activity of the ALK kinase has been shown to contribute to oncogenesis in various lymphoid and non-lymphoid malignancies (reviewed in [86]).

The distinguishing features of ALK+ ALCL, the best defined entity among PTCLs, are the presence of an ALK locus rearrangement at 2p23 and the ensuing aberrant ALK protein expression by the tumour cells [85]. ALK is most frequently juxtaposed to the nucleophosmin (NPM) gene in the t(2;5)(p23;q35) translocation. Less common
partner genes include Tropomyosin 3 (TPM3), TRK fused gene (TFG), ATIC (Pur H gene) and Clathrin heavy chain (CLTC) (reviewed in [5]). The different translocations lead to the deregulated expression of oncogenic fusion proteins, resulting in the constitutive activation of ALK and in the engagement of multiple signalling pathways, including the Jak3/Stat3 and the PI3K/Akt pathways [85].

Although morphologically ALK+ ALCLs span a broad spectrum including several variants, common features include the presence of so-called “hallmark cells” strongly positive for CD30 and the loss of expression of several T-cell antigens [2]. Since conversely other PTCL entities may express CD30, ALK testing is essential to confirm the diagnosis of ALK+ ALCL. ALK rearrangement can routinely be demonstrated by conventional karyotyping, fluorescence in situ hybridization (FISH) or RT-PCR (usually designed for detection of the NPM-ALK fusion transcript only). However, immunohistochemistry assesses ALK protein expression with high sensitivity and specificity and has largely replaced genetic assays. The subcellular location of the immunostaining is indicative of the type of translocation: in cases with the t(2;5)/NPM-ALK translocation ALK staining is both cytoplasmic and nuclear, while most variant translocations entail an ALK positivity restricted to the cytoplasm [87].

The distinction of ALK+ ALCL from other CD30+ PTCLs is prognostically relevant, since patients with the former usually have a much better outcome than patients with ALK- ALCL or PTCL, NOS (5-year OS of approximately 70%, 50% and 30%, respectively) [72].

From a therapeutic perspective, the recent discovery of an oncogenic EML4 (echinoderm microtubule-associated protein-like 4)-ALK translocation in a small subset of lung adenocarcinomas has boosted the efforts for developing ALK-targeting drugs.
Several small-molecule ALK inhibitors are being tested preclinically, and crizotinib (PF-02341066) has yielded promising preliminary results and limited toxicity in patients with non-small-cell lung cancers [88]. ALK+ ALCL patients, particularly when refractory to standard chemotherapy regimens, may also benefit from this novel therapeutic option and will predictably be included in future trials.

**ITK-SYK translocation**

The t(5;9)(q33;q22) translocation, first reported in 2006 in a small subset of PTCLs, NOS, juxtaposes the IL-2-inducible T-cell kinase (*ITK*) gene on chromosome 5 and the spleen tyrosine kinase (*SYK*) gene on chromosome 9 [19]. Itk and Syk are both nonreceptor tyrosine kinases with important functions in lymphocyte development and signal transduction; however, while Itk plays a critical role at all stages of T-cell development and differentiation, the expression of Syk is markedly reduced in normal peripheral T lymphocytes [89, 90]. The Itk-Syk fusion protein, comprising the N-terminal pleckstrin homology domain and proline-rich region of Itk and the tyrosine kinase domain of Syk [19], is a catalytically active tyrosine kinase with transforming properties demonstrated *in vitro* [91] and in transgenic mouse models [92, 93].

Intriguingly, the *ITK-SYK* translocation occurs predominantly in association with the follicular variant of PTCL, NOS (PTCL-F) [19, 67]. Although the characteristic expression of T<sub>FH</sub>-cell markers in PTCL-F suggests a possible relationship with AITL, several clinical, morphologic and biological features distinguish these two entities, and the *ITK-SYK* translocation appears to be restricted to PTCL-F [19, 67, 94].

The t(5;9)/*ITK-SYK* translocation can be demonstrated on paraffin-embedded tissue sections by home-made FISH assays. Hitherto, the diagnostic utility of this test
seems limited, since the translocation is present in only 20% of PTCL-F, which beforehand represent a small minority of PTCLs, NOS [19, 67], and its prognostic significance is unknown. Interestingly, inhibition of Syk is being investigated as a novel potential therapeutic option in PTCLs [95] (see below), and a high sensitivity of tumours with *ITK-SYK* fusion may be expected.

**Rearrangements involving the 6p25.3 locus (**IRF4** or **DUSP22**)**

Novel recurrent chromosomal translocations have recently been reported in approximately 25% of ALK-ALCLs, comprising both systemic and primary cutaneous cases. Surprisingly, although all involve the same genetic locus at 6p25.3, the gene actually affected by the break appears to be variable, corresponding to *IRF4* in about one third of the cases and to *DUSP22* in the remainder [20, 21, 96, 97].

The interferon regulatory factor-4 (*IRF4*) transcription factor, also known as multiple myeloma oncogene-1 (MUM1), is an important regulator of normal lymphoid differentiation, expressed at highest levels in plasma cells and activated T lymphocytes. A subset of multiple myelomas harbours an *IRF4-IGH* translocation and overexpresses MUM1/IRF4 [98]. In rearranged cases of ALK-ALCL, *IRF4*’s translocation partner is mostly unknown, and, somewhat unexpectedly, MUM1/IRF4 expression does not appear to be upregulated [21]. Conversely, when the rearranged gene at 6p25.3 is *DUSP22* (encoding a dual-specificity phosphatase that inhibits TCR signalling), its partner locus is located at 7q32.3 in more than half of the cases, in close proximity of the *FRA7H* fragile site and the microRNA-coding *MIR29* gene. This recurrent t(6;7)(p25.3;q32.3) entails a downregulation of *DUSP22* and an overexpression of *MIR29*, leading to postulate that
the first (DUSP22) might function as a tumour suppressor and the second (MIR29) as an oncogene in translocated ALK-ALCLs [21].

The various 6p25.3 locus rearrangements occur in approximately 20% of systemic and 30% of cutaneous ALK-ALCLs, but only very occasionally in other PTCL entities [20, 21, 96, 97]. As a consequence, the detection of these rearrangements by FISH may be helpful in distinguishing ALK-ALCL from other CD30+ T-cell lymphoproliferations, particularly in the skin. Indeed, among primary cutaneous T-cell lymphoproliferative disorders, FISH positivity for a 6p25.3 translocation is 99% specific for primary cutaneous ALCL [96]. As a correct diagnosis has therapeutic consequences, FISH testing for 6p25.3 rearrangements should be integrated in the diagnostic work-up in this setting. Further investigations are needed, however, to determine the prognostic significance of these rearrangements.

Noteworthy is the report of a translocation involving the TCRA gene at the side of IRF4 (t(6;14)(p25;q11.2)) in two cases of PTCL, NOS with a cytotoxic phenotype and a peculiar, strikingly similar, clinical presentation (bone marrow and skin infiltration), suggesting that these cases may constitute a distinct clinicopathologic entity [20].
**Deregulated signalling pathways**

The molecular characterization of PTCL entities has unravelled the deregulation of several signalling pathways in T-cell lymphomas in comparison with benign T-cell populations, entailing prognostic and/or therapeutic implications (reviewed in [99]).

**Nuclear factor-κB (NF-κB)**

The nuclear factor-κB (NF-κB) family of transcription factors has crucial functions during normal T-cell development and TCR-mediated activation, influencing T-cell proliferation and survival. Several lines of evidence indicate that deregulated NF-κB activity is involved in the pathogenesis of human cancers, including various lymphoid malignancies, by enhancing proliferation and inhibiting apoptosis [100].

Constitutive NF-κB activation is notably induced in cells infected by the human T-lymphotropic virus type 1 (HTLV-1), via the virus-encoded oncoprotein Tax, promoting cell proliferation and oncogenic transformation [100, 101]. HTLV-1 is indeed the causative agent of adult T-cell leukaemia/lymphoma (ATLL), a mostly aggressive PTCL presenting with generalized lymphadenopathy, peripheral blood involvement and often widespread systemic disease. The peculiar geographic distribution of this malignancy (mainly observed in Japan, the Caribbean basin and Central Africa) reflects the prevalence of HTLV-1 infection in the general population [2].

Besides ATLL, NF-κB has also been shown to be aberrantly activated in cutaneous T-cell lymphomas (CTCLs) [102] and in NKTCLs, as recently demonstrated by several GEP studies [11, 18]. NF-κB pathway engagement in NKTCLs is believed to be mediated by the Epstein-Barr virus (EBV), which is invariably associated with this
destructive extranodal (prototypically nasal) cytotoxic lymphoma, most prevalent in Asia and Central-South America [2].

Several NF-κB-blocking compounds have been shown to inhibit proliferation and induce apoptosis in malignant T cells in vitro [101, 102]. Among these agents bortezomib (PS-341, a proteasome inhibitor) has demonstrated promising clinical activity against CTCLs and, in combination with CHOP, in a subset of patients with aggressive systemic PTCLs (including PTCL, NOS, NKTCL, AITL and ALK- ALCL) (reviewed in [78]). Other clinical trials are to be expected in the near future, and will hopefully include ATLL and NKTCL patients.

In one study the global NF-κB signature was found of prognostic value, the overexpression of NF-κB-related genes correlating with a significantly better outcome within most PTCL entities (PTCL, NOS, AITL, NKTCL and CTCL) [12].

Although testing of the NF-κB pathway is not well codified and not yet performed routinely in PTCL samples, several proteins of the NF-κB family can be detected by immunohistochemistry and might be explored in future trials to confirm their prognostic significance [11, 12, 18].

**Spleen tyrosine kinase (Syk)**

The activation of the spleen tyrosine kinase (Syk) is an essential step in the signal transduction from immune receptors, regulating early lymphocyte development. In mature lymphoid cells, Syk is mainly involved in B-cell receptor (BCR) signalling, while in normal T lymphocytes SYK is downregulated and largely supplanted by Zap-70 (a Syk homologue) for transducing T-cell receptor (TCR)-mediated signals [90]. Syk kinase activity is modulated by the differential phosphorylation of critical tyrosine residues.
within the kinase domain and in linker regions, allowing the transition between an autoinhibited and an active conformation [103].

Contrasting with the rarity of the t(5;9)/ITK-SYK translocation, aberrant Syk expression has been recently demonstrated in the vast majority (94%) of a large series of PTCLs representative of most histotypes. An active phosphorylation status of the Syk kinase could be confirmed in 4/4 Syk-positive samples analyzed by Western blot [94]. Moreover, the Syk inhibitor fostamatinib disodium (R406) was shown to inhibit proliferation and induce apoptosis in T-cell lymphoma cell lines [95], leading to an ongoing trial of fostamatinib in PTCL patients [23]. However, the high prevalence of Syk upregulation in PTCLs observed by Feldman et al. [94] was not found by others, who reported Syk expression to be mostly absent [104] or limited to a subset of CD30+ PTCLs [105], a discordance that is perhaps due to the use of different antibodies, detecting functionally distinct forms of Syk. Nevertheless, given the important therapeutic implications of targeting the activated subset of the kinase, this issue needs to be elucidated by further research.

**Platelet-derived growth factor receptor alpha (PDGFRα)**

Platelet-derived growth factor receptor alpha (PDGFRα) is a receptor tyrosine kinase that undergoes dimerization and autophosphorylation upon ligand (PDGF) binding, thereby activating several major signal transduction cascades, including the PI3K/Akt and the Ras-MAPK pathways, which in turn mediate important cell functions such as migration, proliferation and cell survival. Physiological PDGFRα expression is mainly observed in mesenchymal cells and is induced during inflammation. Deregulation of PDGFRα signalling contributes to the pathogenesis of various malignancies, and has been shown to
result from either \textit{PDGFRA} gene amplifications (e.g. in glioblastomas), activating mutations (e.g. in gastrointestinal stromal tumours (GISTs)) or translocations (e.g. \textit{FIP1L1-PDGFR\alpha} translocation in hypereosinophilic syndrome and chronic eosinophilic leukaemia) (reviewed in [106]).

Recent GEP studies have demonstrated an upregulation of \textit{PDGFRA} in several PTCL entities, comprising PTCLs, NOS [15, 17],AITLs [16] and NKTCLs [11], with evidence of an aberrant expression of both PDGFR\alpha and its active phosphorylated form (pPDGFR\alpha) in over 85-90\% of the samples. The mechanisms underlying \textit{PDGFRA} gene deregulation in PTCLs remain unclear, since neither genomic imbalances of its locus at 4q11–q13 nor mutations in the coding sequence or in the promoter region could be evidenced in the PDGFR\alpha-positive samples [11, 107].

Furthermore, \textit{in vitro} studies have demonstrated the sensitivity of malignant T cells to imatinib mesylate, a tyrosine kinase inhibitor with known anti-PDGFR\alpha activity. Imatinib induced a concentration-dependent growth inhibition and/or cell death of PTCL, NOS primary cells and NKTCL cell lines, with only a limited effect on the viability of normal lymphocytes [11, 17].

Altogether, these data point towards PDGFR\alpha as a new candidate for targeted treatment strategies in patients with PTCLs. Further preclinical and clinical validation is needed to confirm the potential role of imatinib or other more recently developed tyrosine kinase inhibitors in this setting.
Summary

The pathological diagnosis of PTCLs is often challenging, and with few exceptions affected patients have a dismal outcome. Genome-wide molecular analyses have consented to identify novel biomarkers that may improve the practical management of these patients. Cutaneous PTCLs of γδ derivation must be distinguished from their αβ counterparts because of a more aggressive behaviour. Cytotoxic proteins are variably expressed by several PTCL entities, and appear to confer a poorer prognosis when detected in PTCLs, NOS. Granzyme H may be helpful in distinguishing NKTCL from other cytotoxic PTCL subtypes, and a restricted KIR repertoire can be used as a surrogate marker of clonality in NK-cell proliferations. The expression of T_{FH}-cell markers is routinely explored to ascertain the diagnosis of AITL, as a reflection of its histogenetic derivation. Other molecules variably expressed at the surface of PTCLs can be targeted by immunotherapeutic agents. Particularly antibodies or antibody conjugates directed against CD52 and CD30 have shown promising results in clinical trials. At the genetic level, previously unrecognized chromosomal translocations are being discovered in several PTCL subtypes, providing hints to their pathogenesis as well as novel diagnostic markers. The ITK-SYK translocation is associated with the follicular variant of PTCL, NOS, while recurrent IRF4 and DUSP22 rearrangements have newly been reported in subsets of cutaneous and systemic ALK- ALCLs. Molecules deregulated in oncogenic pathways are increasingly being identified through GEP studies, including transcription factors and tyrosine kinases such as NF-κB, PDGFRα and Syk. Specific inhibitors targeting these proteins are being evaluated as novel therapeutic options.
Practice points

- γδ PTCLs are highly aggressive disease, irrespective of their site of origin, and can be ascertained in routinely processed tissues by immunohistochemistry since recently.

- Subsets of PTCLs express CD30 or CD52 on their surface and therapeutic antibodies targeting these molecules (brentuximab and alemtuzumab, respectively) have shown promising clinical activity.

- Recurrent chromosomal translocations, traditionally considered as a hallmark of B-cell lymphomas, are being discovered in several PTCL entities.

- Gene expression studies have identified oncogenic pathways deregulated in PTCLs, disclosing potential targets for novel therapies, including tyrosine kinase and proteasome inhibitors.
Research agenda

- PTCLs are rare and heterogeneous diseases with a dismal prognosis. International collaborative efforts are needed to gather large homogeneous cohorts of patients and tumour samples, to allow meaningful clinical and translational research.

- The distinction of cytotoxic versus non-cytotoxic PTCLs, NOS has appeared to be biologically significant, but testing of larger series is required to establish its clinical relevance.

- Next-generation genome-wide technologies will be disclosing novel oncogenic mechanisms, predictive markers and therapeutic targets in the near future, opening the way for individually tailored treatments for PTCL patients as well.

Acknowledgements

This work was supported by the Belgian National Fund for Scientific Research (Fonds de la Recherche Scientifique, FNRS), the Belgian Cancer Plan, and the French Foundation for Medical Research (Fondation pour la Recherche Médicale, FRM). Bettina Bisig and Laurence de Leval are a Scientific Research Worker-Télévie and a Senior Research Associate of the FNRS, respectively.
# Tables and figures

## Table 1.

Current WHO classification and worldwide frequency of peripheral T-cell and NK-cell lymphomas (adapted from Swerdlow *et al.* [2]).

<table>
<thead>
<tr>
<th>Predominant presentation</th>
<th>PTCL entity</th>
<th>Frequency (%)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disseminated/leukaemic</td>
<td>T-cell prolymphocytic leukaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T-cell large granular lymphocytic leukaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic lymphoproliferative disorders of NK cells*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aggressive NK-cell leukaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systemic EBV-positive T-cell lymphoproliferative disease of childhood</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adult T-cell leukaemia/lymphoma</td>
<td>9.6</td>
</tr>
<tr>
<td></td>
<td>Extranodal NK/T-cell lymphoma, nasal type</td>
<td>10.4</td>
</tr>
<tr>
<td></td>
<td>Enteropathy-associated T-cell lymphoma</td>
<td>4.7</td>
</tr>
<tr>
<td></td>
<td>Hepatosplenic T-cell lymphoma</td>
<td>1.4</td>
</tr>
<tr>
<td></td>
<td>Cutaneous</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subcutaneous panniculitis-like T-cell lymphoma</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>Mycosis fungoides</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sézary syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary cutaneous CD30+ T-cell lymphoproliferative disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary cutaneous anaplastic large cell lymphoma</td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td>Lymphomatoid papulosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary cutaneous γδ T-cell lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary cutaneous CD4+ small/medium T-cell lymphoma*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydroa vacciniforme-like lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nodal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peripheral T-cell lymphoma, not otherwise specified</td>
<td>25.9</td>
</tr>
<tr>
<td></td>
<td>Angioimmunoblastic T-cell lymphoma</td>
<td>18.5</td>
</tr>
<tr>
<td></td>
<td>Anaplastic large-cell lymphoma, ALK-positive</td>
<td>6.6</td>
</tr>
<tr>
<td></td>
<td>Anaplastic large-cell lymphoma, ALK-negative*</td>
<td>5.5</td>
</tr>
</tbody>
</table>

ALK, anaplastic lymphoma kinase; EBV, Epstein-Barr virus; NK, natural killer.

* Provisional entities.

** According to Vose *et al.* [3]. Statistics are based on pathologic anatomy registries, with under-representation of leukaemic and cutaneous entities.
Table 2.
Summary of the biomarkers discussed in this review and their clinical relevance in the diagnosis, prognosis or treatment of peripheral T-cell lymphoma entities.

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Associated PTCL entities</th>
<th>Clinical significance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lineage / differentiation markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCRγ and TCRδ chains</td>
<td>HSTL, Primary cutaneous γδ TCL, Other non-HS γδ PTCLs</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>NK-cell receptors: KIRs</td>
<td>NK-cell lymphoproliferations, T-LGL (restricted KIR repertoire), Sézary syndrome (aberrant expression of CD158k/KIR3DL2)</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>Cytotoxic molecules: TIA-1, perforin, granzyme B, granzyme H</td>
<td>Cfr. Table 3</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>T_{FH}-cell markers: CXCL13, PD-1, ICOS, CD200, SAP, Bcl-6, c-Maf</td>
<td>AITL, PTCL-F, Primary cutaneous CD4+ small/medium TCL</td>
<td>Diagnosis</td>
</tr>
<tr>
<td><strong>Cell-surface markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD30</td>
<td>ALK+ and ALK-ALCL, Subset of PTCL, NOS, Primary cutaneous CD30+ T-cell lymphoproliferative disorders</td>
<td>Diagnosis, Therapy: brentuximab vedotin targets CD30</td>
</tr>
<tr>
<td>CD52</td>
<td>Subset of AITL, PTCL, NOS, NKTCL, ATLL, Minority of ALCL</td>
<td>Therapy: alemtuzumab targets CD52</td>
</tr>
<tr>
<td><strong>Chromosomal translocations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALK rearrangement</td>
<td>ALK+ ALCL</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>ITK-SYK translocation</td>
<td>Subset of PTCL-F</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>IRF4 or DUSP22</td>
<td>Subset of systemic and cutaneous</td>
<td>Diagnosis</td>
</tr>
</tbody>
</table>
## Signalling pathways

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Tumours</th>
<th>Prognosis</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NF-κB</strong></td>
<td>ATLL, NKTL, Cutaneous TCL, PTCL, NOS, AITL, ALK-ALCL</td>
<td><strong>Prognosis:</strong> “NF-κB high” PTCLs have better outcome</td>
<td><strong>Therapy:</strong> bortezomib blocks NF-κB pathway</td>
</tr>
<tr>
<td><strong>Syk</strong></td>
<td>Majority of PTCLs (Feldman, 2008), Subset of CD30+ PTCLs (Geissinger, 2010)</td>
<td><strong>Therapy:</strong> fostamatinib inhibits Syk activity</td>
<td></td>
</tr>
<tr>
<td><strong>PDGFRα</strong></td>
<td>PTCL, NOS, AITL, NKTL</td>
<td><strong>Therapy:</strong> imatinib inhibits PDGFRα activity</td>
<td></td>
</tr>
</tbody>
</table>

AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukaemia/lymphoma; HSTL, hepatosplenic T-cell lymphoma; KIR, killer cell immunoglobulin-like receptor; NK, natural killer; NKTL, extranodal NK/T-cell lymphoma; non-HS, non-hepatosplenic; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma; PTCL-F, follicular variant of PTCL, NOS; TCL, T-cell lymphoma; TCR, T-cell receptor; TFH, follicular helper T cell; T-LGL, T-cell large granular lymphocytic leukaemia.
Table 3.
Overview of major peripheral T-cell lymphoma entities associated with a cytotoxic phenotype and presenting with tissue involvement.

<table>
<thead>
<tr>
<th>PTCL entity</th>
<th>Predominant presentation</th>
<th>Postulated cell of origin</th>
<th>Cytotoxic phenotype*</th>
<th>EBV status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKTCL, nasal type</td>
<td>Extranodal</td>
<td>NK cells (rarely γδ or αβ T cells)</td>
<td>Activated</td>
<td>Positive</td>
</tr>
<tr>
<td>EATL</td>
<td>Extranodal</td>
<td>αβ T cells (rarely γδ T cells)</td>
<td>Activated</td>
<td>Negative</td>
</tr>
<tr>
<td>HSTL</td>
<td>Extranodal</td>
<td>γδ T cells (rarely αβ T cells)</td>
<td>Non-activated</td>
<td>Negative</td>
</tr>
<tr>
<td>Subcutaneous panniculitis-like TCL</td>
<td>Cutaneous</td>
<td>αβ T cells</td>
<td>Activated</td>
<td>Negative</td>
</tr>
<tr>
<td>Primary cutaneous CD30+ T-cell lymphoproliferative disorders</td>
<td>Cutaneous</td>
<td>αβ T cells</td>
<td>Activated</td>
<td>Negative</td>
</tr>
<tr>
<td>Primary cutaneous γδ TCL</td>
<td>Cutaneous</td>
<td>γδ T cells</td>
<td>Activated</td>
<td>Negative</td>
</tr>
<tr>
<td>PTCL, NOS (subset)</td>
<td>Nodal</td>
<td>αβ T cells</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>ALK+ ALCL</td>
<td>Nodal</td>
<td>αβ T cells</td>
<td>Activated</td>
<td>Negative</td>
</tr>
<tr>
<td>ALK- ALCL</td>
<td>Nodal</td>
<td>αβ T cells</td>
<td>Activated</td>
<td>Negative</td>
</tr>
</tbody>
</table>

ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; EATL, enteropathy-associated T-cell lymphoma; EBV, Epstein-Barr virus; HSTL, hepatosplenic T-cell lymphoma; NKTCL, extranodal NK/T-cell lymphoma; non-HS, non-hepatosplenic; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma; TCL, T-cell lymphoma.

* Activated cytotoxic phenotype: expression of perforin and/or granzyme B in addition to TIA-1; non-activated cytotoxic phenotype: expression of TIA-1 only.
Fig. 1.
Overview of normal T-cell and NK-cell differentiation and putative histogenetic derivation of the major PTCL entities (reproduced with permission from de Leval et al. [25]).

AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; HTLV1, human T-lymphotropic virus type 1; NK, natural killer cell; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma; TCL, T-cell lymphoma; TFH, follicular helper T cell; Treg, regulatory T cell.
References


